← Back to Analyst Consensus 
ELOX Buy
Eloxx Pharmaceuticals, Inc.
Current Price —
Implied Upside —
Analysts 10
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 15, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
| Sep 18, 2026 | Leerink Partners | initiate | — → Outperform | — | 51% |
| Aug 24, 2026 | Guggenheim | reiterate | Buy → Buy | — | 52% |
| Aug 20, 2026 | LUCID CAPITAL MARKETS | initiate | — → Buy | — | 33% |
| Jul 22, 2026 | LifeSci Capital | initiate | — → Outperform | — | 57% |
| Jul 20, 2026 | Guggenheim | initiate | — → Buy | — | 52% |
| Jul 11, 2023 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| Apr 6, 2023 | Oppenheimer | reiterate | — → Outperform | — | 52% |
Price Target Trend
Jul 23, 2026 Oct 26, 2026
EPS Estimates
0y —
0q —
+1q —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days